Cervical Cancer Vaccine To Undergo Evaluation
September 25, 2007 by Gloria Gamat
Filed under Diseases & Conditions
Speaking of cervical cancer vaccines, there are two notables: Gardasil by Merck which was approved by the FDA earlier this year and Cervarix by GlaxoSmithKline which is expected to be approved by the FDA later this year (but already approved in Australia).
Regarding these HPV vaccines that will protect women against cervical cancer, the CDC recommends that the vaccine should be routinely given to girls at 11-12 years of age – the stage before young girls are more likely to become sexually active.
Now there is a new project that will evaluate and monitor the effectiveness of these vaccines.
The said project -funded by the national Centers for Disease Control and Prevention (CDC) – will be jointly conducted by the University of Rochester Medical Center (URMC) and the New York State Department of Health.
The said project is an attempt to determine how many people are receiving the vaccine and whether or not it is having a measurable impact on rates of cervical cancer and its precursor lesions.
Find more details from University of Rochester Medical Center.
[Photo Credit: URMC]
Cost Factor for Developing World?
Against how many sub-types of HPV ultimately?
Possibilities for mutation in future, requiring change for vaccine.
Requires wide, multi-centric trial before final comments.